| NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 00245-0824-30 | 00245-0824 | Everolimus | TORPENZ | 7.5 mg/1 | Chemotherapy | Enzyme Inhibitor | mTOR | Oral | Jun 24, 2024 | In Use | |
| 50242-0210-12 | 50242-0210 | Pralsetinib | Gavreto | 100.0 mg/1 | Chemotherapy | Enzyme Inhibitor | RET, DDR1, TRKC, FLT3, JAK1/2, TRKA, VEGFR2, PDGFRB, FGFR1 | Oral | Sep 28, 2022 | In Use | |
| 50242-0210-60 | 50242-0210 | Pralsetinib | Gavreto | 100.0 mg/1 | Chemotherapy | Enzyme Inhibitor | RET, DDR1, TRKC, FLT3, JAK1/2, TRKA, VEGFR2, PDGFRB, FGFR1 | Oral | Jul 1, 2021 | In Use | |
| 00310-0679-12 | 00310-0679 | Olaparib | Lynparza | 150.0 mg/1 | Chemotherapy | Enzyme Inhibitor | PARP | Oral | Aug 17, 2017 | In Use | |
| 00093-7769-24 | 00093-7769 | Everolimus | Everolimus | 10.0 mg/1 | Chemotherapy | Enzyme Inhibitor | mTOR | Oral | Oct 23, 2023 | In Use | |
| 82950-0012-01 | 82950-0012 | Tovorafenib | OJEMDA | 25.0 mg/ml | Chemotherapy | Enzyme Inhibitor | BRAF, CRAF | ORAL | Apr 30, 2024 | In Use | |
| 73555-0501-00 | 73555-0501 | Revumenib | Revuforj | 110.0 mg/1 | Chemotherapy | Enzyme Inhibitor | KMT2A | Oral | Nov 15, 2024 | In Use | |
| 81864-0103-30 | 81864-0103 | Momelotinib | Ojjaara | 100.0 mg/1 | Chemotherapy | Enzyme Inhibitor | JAK 1/2 | Oral | Sep 15, 2023 | In Use | |
| 00378-3099-85 | 00378-3099 | Everolimus | Everolimus | 10.0 mg/1 | Chemotherapy | Enzyme Inhibitor | mTOR | Oral | Dec 15, 2022 | Feb 28, 2025 | No Longer Used |
| 51991-0823-33 | 51991-0823 | Everolimus | Everolimus | 7.5 mg/1 | Chemotherapy | Enzyme Inhibitor | mTOR | Oral | Jun 5, 2023 | In Use | |
| 69660-0201-91 | 69660-0201 | Rucaparib | Rubraca | 200.0 mg/1 | Chemotherapy | Enzyme Inhibitor | PARP | Oral | Dec 19, 2016 | Dec 31, 2025 | In Use |
| 51991-0822-28 | 51991-0822 | Everolimus | Everolimus | 5.0 mg/1 | Chemotherapy | Enzyme Inhibitor | mTOR | Oral | Mar 5, 2021 | In Use | |
| 59572-0705-30 | 59572-0705 | Enasidenib mesylate | Idhifa | 50.0 mg/1 | Chemotherapy | Enzyme Inhibitor | IDH2 | Oral | Aug 1, 2017 | In Use | |
| 51991-0824-33 | 51991-0824 | Everolimus | Everolimus | 10.0 mg/1 | Chemotherapy | Enzyme Inhibitor | mTOR | Oral | Jun 5, 2023 | In Use | |
| 00078-0567-61 | 00078-0567 | Everolimus | Afinitor | 10.0 mg/1 | Chemotherapy | Enzyme Inhibitor | mTOR | Oral | Mar 22, 2010 | In Use | |
| 00078-0620-61 | 00078-0620 | Everolimus | Afinitor | 7.5 mg/1 | Chemotherapy | Enzyme Inhibitor | mTOR | Oral | Jul 29, 2011 | In Use | |
| 73116-0215-56 | 73116-0215 | Duvelisib | COPIKTRA | 15.0 mg/1 | Chemotherapy | Enzyme Inhibitor | PI3K | Oral | Sep 25, 2018 | In Use | |
| 00054-0480-14 | 00054-0480 | Everolimus | Everolimus | 2.5 mg/1 | Chemotherapy | Enzyme Inhibitor | mTOR | Oral | Jun 8, 2020 | In Use | |
| 00054-0481-14 | 00054-0481 | Everolimus | Everolimus | 5.0 mg/1 | Chemotherapy | Enzyme Inhibitor | mTOR | Oral | Jun 8, 2020 | In Use | |
| 50881-0010-01 | 50881-0010 | Ruxolitinib | Jakafi | 10.0 mg/1 | Chemotherapy | Enzyme Inhibitor | JAK 1 and JAK 2 (Janus Kinase Inhibitor) | Oral | Nov 16, 2011 | In Use | |
| 63539-0051-30 | 63539-0051 | Talazoparib | Talzenna | 0.5 mg/1 | Chemotherapy | Enzyme Inhibitor | PARP | Oral | Jun 21, 2023 | Jun 30, 2026 | In Use |
| 70377-0013-23 | 70377-0013 | Everolimus | EVEROLIMUS | 10.0 mg/1 | Chemotherapy | Enzyme Inhibitor | mTOR | Oral | May 17, 2024 | In Use | |
| 63850-0059-01 | 63850-0059 | Everolimus | Everolimus | 5.0 mg/1 | Chemotherapy | Enzyme Inhibitor | mTOR | Oral | Mar 5, 2021 | In Use | |
| 00093-7767-24 | 00093-7767 | Everolimus | Everolimus | 5.0 mg/1 | Chemotherapy | Enzyme Inhibitor | mTOR | Oral | Jun 10, 2020 | In Use | |
| 00074-0576-22 | 00074-0576 | Venetoclax | Venclexta | 100.0 mg/1 | Chemotherapy | Enzyme Inhibitor | BCL-2 | Oral | Apr 11, 2016 | In Use |
Found 11765 results — Export these results
Home